Repair & Recovery

Receptor Selectivity & Comparative Biochemistry

The four principal compounds within this category represent biochemically distinct classes of repair-associated peptides, each engaging discrete molecular targets implicated in tissue homeostasis, extracellular matrix remodelling, and inflammatory resolution. The comparative overview below summarises their primary receptor interactions, structural identities, and predominant research applications.

Compound	Primary Receptor Target	Molecular Formula	Molecular Mass	Primary Research Focus
BPC-157	VEGFR-2 / FAK–paxillin pathway; NO-synthase modulation	C62H98N16O22	1,419.5 Da	Tendon, ligament, and gastrointestinal mucosal repair; angiogenesis
TB-500	G-actin sequestration (β-thymosin domain); LMNA / integrin β4	C212H350N56O78S	4,963.5 Da	Skeletal muscle regeneration, cardiac repair, actin cytoskeletal dynamics
GHK-Cu	Copper(II) chelation complex; TGF-β1 / SPARC upregulation; p53 pathway modulation	C14H23CuN6O4	340.8 Da (Cu complex)	Collagen synthesis, wound healing, anti-ageing dermal remodelling, antioxidant gene expression
KPV	MC1R / MC3R (melanocortin receptors); NF-κB inhibition	C16H30N4O4	342.4 Da	Anti-inflammatory signalling, intestinal epithelial repair, innate immune modulation

BPC-157 exerts its pro-angiogenic and cytoprotective effects principally through upregulation of VEGFR-2 and downstream focal adhesion kinase (FAK)–paxillin signalling, facilitating fibroblast migration and neovascularisation at injury sites. TB-500, the synthetic analogue of thymosin β4, sequesters monomeric G-actin via its conserved LKKTET motif, thereby regulating cytoskeletal polymerisation dynamics critical to myocyte and endothelial cell migration. GHK-Cu operates as a copper(II) chelate that activates TGF-β1-mediated collagen and glycosaminoglycan biosynthesis whilst simultaneously modulating over 4,000 human genes associated with tissue remodelling and oxidative stress response. KPV (Lys-Pro-Val), a C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH), engages melanocortin receptors MC1R and MC3R to suppress NF-κB nuclear translocation, attenuating pro-inflammatory cytokine cascades including IL-1β, IL-6, and TNF-α.

Reconstitution & Laboratory Handling Protocols

All compounds in this category are supplied as lyophilised powders and require careful reconstitution under aseptic conditions. The following protocols reflect current best practice for research-grade peptide handling.

General Reconstitution Procedure: Allow sealed vials to equilibrate to ambient temperature (18–22 °C) for a minimum of 15 minutes prior to opening, preventing condensation-driven hydrolysis. Using a sterile 23–25 gauge needle, introduce bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4) slowly along the inner vial wall — never directly onto the lyophilised cake — to minimise mechanical shear and peptide aggregation. Gently swirl; do not vortex. For BPC-157 and KPV, a concentration of 0.5–1.0 mg/mL in bacteriostatic water is standard for in vitro stock preparation. TB-500, owing to its higher molecular mass and amphipathic character, reconstitutes optimally in sterile PBS at 37 °C with gentle agitation over 5–10 minutes.

Storage of Reconstituted Solutions: Reconstituted BPC-157 and KPV solutions should be stored at 2–8 °C and used within 28 days; TB-500 solutions retain integrity for up to 21 days under identical conditions. All reconstituted solutions should be protected from light and must not be subjected to freeze-thaw cycling, which promotes aggregation and β-sheet misfolding. Aliquoting into single-use volumes prior to storage is strongly recommended.

Lyophilised Powder Storage: Unopened lyophilised vials of BPC-157, TB-500, and KPV should be stored at −20 °C, away from moisture and UV exposure. GHK-Cu requires specialised storage conditions as detailed below.

Operational Decision: GHK-Cu Specialised Packaging Protocol GHK-Cu (copper peptide) is a highly reactive compound capable of catalysing the oxidative degradation of co-stored peptides through Fenton-type copper-mediated radical generation. Even trace atmospheric oxygen is sufficient to initiate ligand oxidation and copper redox cycling, compromising both the GHK-Cu complex itself and any proximate peptide species. In response to this well-characterised reactivity profile, we made the operational decision to supply GHK-Cu exclusively in high-vacuum lyophilised vials processed with a customised nitrogen-purge cycle. This procedure displaces residual atmospheric oxygen within the vial headspace prior to final sealing, ensuring an inert anaerobic microenvironment throughout the product's shelf life. This approach guarantees absolute chemical stability during long-term storage and eliminates the risk of copper-catalysed oxidative degradation — a standard not universally applied across the industry but one we consider non-negotiable for research integrity.

GHK-Cu Reconstitution: Due to the copper(II) coordination chemistry of GHK-Cu, reconstitution should be performed using ultrapure water (HPLC-grade or equivalent, ≥18.2 MΩ·cm resistivity) rather than PBS, as phosphate anions can compete with the peptide for copper coordination, potentially disrupting the Cu(II) chelate complex. Reconstituted GHK-Cu solutions should be used within 7 days when stored at 2–8 °C in amber vials to minimise photocatalytic oxidation. Do not co-store reconstituted GHK-Cu solutions with other peptides in the same container or refrigerator shelf without adequate separation.

Sterility & Filtration: Where sterile filtration is required, use a 0.22 μm PVDF (polyvinylidene fluoride) membrane syringe filter. Avoid cellulose acetate membranes for GHK-Cu, as copper ions may interact with the membrane matrix, reducing effective concentration. All handling should be conducted within a Class II biological safety cabinet or equivalent laminar flow environment. Full Certificates of Analysis (CoA) and reconstitution data sheets are available for each batch. Refer to our Repair & Recovery Research Guide for extended protocol guidance.

Analytical Quality & Compliance Standards

AbsoluteBioLab operates under a rigorous multi-stage analytical quality framework applied to every batch of repair and recovery peptides prior to release. Our quality assurance pipeline is designed to meet and exceed the standards expected for research-grade biochemical reagents, providing investigators with the confidence required for reproducible, publication-quality experimental outcomes.

HPLC Purity Verification: Every batch undergoes reverse-phase high-performance liquid chromatography (RP-HPLC) using a C18 stationary phase with UV detection at 214 nm and 280 nm. Our minimum release standard is ≥99.0% chromatographic purity by peak area integration. Batches failing to meet this threshold are rejected in their entirety and are not offered for sale. HPLC chromatograms are appended to each batch-specific Certificate of Analysis (CoA), which is freely accessible via QR code on product packaging and through our online CoA portal.

Mass Spectrometry Identity Confirmation: Structural identity is independently confirmed by electrospray ionisation mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) analysis, as appropriate to the molecular mass range of each compound. Observed molecular ion masses are required to fall within ±0.1 Da of the theoretical monoisotopic mass, confirming correct primary sequence and the absence of truncation, deletion, or racemisation artefacts. For GHK-Cu, ESI-MS confirms both the free tripeptide mass and the intact copper(II) coordination complex ion.